drugset / Trial / NCT01285466

A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab

NCT01285466

Phase 1 Completed 110 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.

Timeline

Start
2011-01
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Buparlisib Small molecule
Subject Dactolisib Small molecule
Subject Trastuzumab Monoclonal antibody
Background Paclitaxel Small molecule